13 Apr 2023 • Tranexamic acid appears no more effective than placebo in reducing the need for blood transfusion or preventing maternal death in patients with increased risk for excessive bleeding because of cesarean delivery, according to a study published in NEJM today. Previously, researchers have theorized that since tranexamic acid prevents the breakdown of blood clots, the drug might slow blood loss and reduce the risk of postpartum hemorrhage.

• Researchers assigned 11,000 patients to receive either intravenous tranexamic acid or placebo after umbilical cord clamping at the time of cesarean delivery. The study included women who had undergone scheduled and unscheduled cesarean delivery.
• The researchers reported the results as a single primary outcome of events that might be expected with postpartum hemorrhage, the need for a transfusion of red blood cells or death - These events occurred in 201 patients (3.6%) in the tranexamic acid group and 233 (4.3%) in the placebo group, a difference that was not statistically significant.
• For the placebo group, one death occurred. There were no deaths in the tranexamic acid group.
• There was no significant difference between the groups for the secondary outcome of estimated blood loss of more than 1 liter during the procedure: 7.3% in the tranexamic acid group, 8% in the placebo group.
• However, the study found that patients who received tranexamic acid had less need for additional medical or surgical interventions to treat postpartum hemorrhage, compared to the placebo group (16.1% versus 18%), and a lower drop in red blood cell count after cesarean delivery (1.8 grams per deciliter versus 1.9 grams per deciliter).

Source: NIH | Read full article